<DOC>
	<DOCNO>NCT00002890</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate cancer cell either kill deliver cancer-killing substance without harm normal cell . PURPOSE : Phase I trial study effectiveness radiolabeled monoclonal antibody treat patient myelodysplastic syndrome relapse refractory acute myeloid leukemia chronic myelogenous leukemia .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Treating Patients With Myelodysplastic Syndrome Relapsed Refractory Acute Myeloid Leukemia Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety toxicity yttrium-90-labeled humanized monoclonal antibody M195 ( 90Y-MOAB HuM195 ) patient relapse refractory myeloid malignancy . II . Determine pharmacology dosimetry 90Y-MOAB HuM195 . III . Study biological effect 90Y-MOAB HuM195 , include ability elicit human anti-human antibody response antileukemic response . OUTLINE : This study seek estimate maximum tolerate dose ( MTD ) yttrium-90-labeled humanized monoclonal antibody M195 ( 90Y-MOAB HuM195 ) . All patient receive single intravenous dose 90Y-MOAB HuM195 . Groups 3 6 patient treat escalated dos yttrium-90 MTD determine . Patients active leukemia exhibit least 50 % clearing marrow blast first dose may receive second dose 4-8 week provide remain blast CD33-positive , evidence human anti-human antibody response , toxicity resolve . All patient follow monthly 4 month treatment . PROJECTED ACCRUAL : Up 24 patient treat . The study expect require 12-18 month complete .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Pathologically confirm myeloid malignancy follow : Acute myelogenous leukemia relapse refractory least 2 course standard induction chemotherapy Accelerated myeloblastic chronic myelogenous leukemia Refractory anemia excess blast ( RAEB ) RAEB transformation Chronic myelomonocytic leukemia More 25 % bone marrow blast positive CD33 antigen Clear sign active leukemia follow recovery prior therapy require No rapidly accelerate blast count No clinically unstable disease No active CNS leukemia PATIENT CHARACTERISTICS : Age : Over 16 Performance status : Karnofsky 60 % 100 % Life expectancy : At least 6 week Hematopoietic : Not specify Hepatic : Bilirubin le 2.5 mg/dL AST le 3 time normal Alkaline phosphatase less 3 time normal Renal : Creatinine le 2.0 mg/dL Cardiovascular : No NYHA class III/IV status Pulmonary : No clinically significant pulmonary disease Other : No serious infection uncontrolled antibiotic No pregnant nursing woman Negative pregnancy test require fertile woman PRIOR CONCURRENT THERAPY : Recovered prior therapy Biologic therapy : No detectable antibody M195 prior monoclonal antibody M195 HuM195 Chemotherapy : At least 2 day since hydroxyurea At least 3 week since chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 3 week since radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>